AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Mizuho Securities Reiterates Neutral Rating on Amgen (AMGN), PT $208, 'Lukewarm Lumakras ESMO Data'
September 12, 2022 9:44 AM EDTMizuho Securities analyst Salim Syed reiterated a Neutral rating and $208.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "And last night, we received the first part of detailed data from Amgen's Ph3 CB200 trial (Lumakras in 2L+ NSCLC). While we expect to receive the second part of detailed data later today, the first part showed (a) a decrease in ORR from 36% in CB100 to yesterday's 28%, (b) Gr3 liver enzyme elevations in about 10% of patients -- known... More
